SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-033519
Filing Date
2022-10-05
Accepted
2022-10-05 09:01:58
Documents
14
Period of Report
2022-10-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acer-8k_20221005.htm   iXBRL 8-K 40369
2 EX-99.1 acer-ex991_15.htm EX-99.1 32941
3 GRAPHIC g3ort5e4yfiu000001.jpg GRAPHIC 22841
  Complete submission text file 0001564590-22-033519.txt   244091

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA acer-20221005.xsd EX-101.SCH 5581
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE acer-20221005_lab.xml EX-101.LAB 20086
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acer-20221005_pre.xml EX-101.PRE 11931
8 EXTRACTED XBRL INSTANCE DOCUMENT acer-8k_20221005_htm.xml XML 3694
Mailing Address ONE GATEWAY CENTER (300 WASHINGTON ST.) SUITE 356 NEWTON MA 02458
Business Address ONE GATEWAY CENTER (300 WASHINGTON ST.) SUITE 356 NEWTON MA 02458 (844) 902-6100
Acer Therapeutics Inc. (Filer) CIK: 0001069308 (see all company filings)

IRS No.: 320426967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33004 | Film No.: 221294600
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences